Comparison of the effect of Roux‐en‐Y gastric bypass and sleeve gastrectomy on remission of type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials
Autor: | Jens Kristoffer Hertel, Dag Hofsø, Heidi Borgeraas, Jøran Hjelmesæth |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
Sleeve gastrectomy type 2 diabetes mellitus Endocrinology Diabetes and Metabolism medicine.medical_treatment Bariatric Surgery/Obesity Comorbidity MEDLINE 030209 endocrinology & metabolism Type 2 diabetes Gastroenterology law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial systematic review law Internal medicine medicine 030212 general & internal medicine business.industry Public Health Environmental and Occupational Health Type 2 Diabetes Mellitus nutritional and metabolic diseases medicine.disease Roux-en-Y anastomosis Roux‐en‐Y gastric bypass Relative risk Meta-analysis business sleeve gastrectomy |
Zdroj: | Obesity Reviews |
ISSN: | 1467-789X 1467-7881 |
Popis: | Summary Bariatric surgery is an effective treatment option for patients with type 2 diabetes mellitus (T2DM) and obesity. This study aims to compare the effects of Roux‐en‐Y gastric bypass (RYGB) and sleeve gastrectomy (SG) on remission of T2DM. MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched for studies published between database inception and 21 November 2019. A meta‐analysis, using a random effects model, was performed to calculate relative risk (RR) of T2DM remission between the groups in randomized controlled trials (RCTs). Of 2650 records identified, 12 records from 10 different RCTs were finally included. The studies comprised 705 patients with follow‐up from 1 to 5 years. The remission rate of T2DM at 1 year was higher among those undergoing RYGB (156/276, 57%) compared with those undergoing SG (128/275, 47%), RR (95% CI) 1.20 (1.00‐1.45), P = .047, I 2 = 24.9%, moderate‐quality evidence. Among studies with 2‐ to 5‐year follow‐up, there was no difference in remission rates between the RYGB (132/263, 50%) and SG (121/266, 46%) groups, RR 1.06 (0.94‐1.20), P = .34, I 2 = 0.0%, low‐quality evidence. RYGB resulted in a higher rate of T2DM remission compared with SG after 1 year. The T2DM remission rates did not differ in studies with 2‐ to 5‐year follow‐up. |
Databáze: | OpenAIRE |
Externí odkaz: |